| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 updated data readout example | KIO-104 Retinal macular edema (including posterior non‑infectious uveitis and diabetic macular edema) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System | |
Phase 2 updated data readout example | KIO-104 Retinal macular edema (including posterior non‑infectious uveitis and diabetic macular edema) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System | |
Phase 2 updated data readout example | KIO-104 Retinal macular edema (including posterior non‑infectious uveitis and diabetic macular edema) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Kiora Pharmaceuticals, Inc.$2.51
-0.04 (-1.57%)
D 32Pipeline Score Fair Value Pharma · Clinical
Market Cap
11.35 M
EPS
-2.84
P/E Ratio
-
Value Trade
47.06 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
2.12 M
Operating CF
-3.16 M
Total Assets
21.23 M
Total Liabilities
7.29 M
Equity
13.93 M
D/E Ratio
12,345
-0.39 %
Week
2.67 %
1 Month
24.27 %
3 Month
42.22 %
6 Month
-99.83 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
13.87 M
Monthly Burn
1.05 M
Runway
11.3 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
4.03 K
52 Week Range
1.76 - 4.18
% held by Insiders
5.81 %
% held by Institutions
32.39 %
Enterprise Value
-2.15 M
Total Shares
4.43 M
Short %
0.5 %
Float Shares
4.29 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kiora Pharmaceuticals, Inc.
337Total events
5Upcoming
109Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 5
Event history 332
Jun 18, 2026
▲Poster PresentationKIO-300Presentation
Poster presentation of KIO-300 preclinical data in epilepsy model at Epilepsy Foundation Pipeline Conference
temporal lobe epilepsysource ↗
May 8, 2026
▲Enrollment UpdateKIO-301Trial
Enrollment in ABACUS-2 close to 50% completed
retinitis pigmentosasource ↗
Apr 17, 2026
◆Management ChangeCorporate
Chief Development Officer Eric J. Daniels to depart on April 17, 2026
Apr 6, 2026
▼Equity OfferingCorporate
Closed private placement for up to $24 million led by Perceptive Advisors
Apr 2, 2026
▲Enrollment UpdateKIO-301Trial
ABACUS-2 Phase 2 trial received approval to enroll remaining patients in 50 µg dose cohort and clearance to initiate 100 µg dose cohort
retinitis pigmentosasource ↗
Apr 2, 2026
▲Enrollment UpdateKIO-104Trial
KLARITY Phase 2 trial cleared all planned safety review checkpoints; patient enrollment ongoing
macular edema due to retinal inflammationsource ↗
Apr 2026
▲PublicationKIO-301Presentation
Publication of ABACUS-1 results in Nature Medicine
retinitis pigmentosasource ↗
Mar 25, 2026
●Runway Guidance UpdateCorporate
Cash runway into late 2027, beyond anticipated data readouts
2026
◆Safety Data UpdateKIO-104Clinical Data
Upcoming pre-defined safety review for dose escalation
macular edema due to retinal inflammationsource ↗
2026
◆Topline ReadoutKIO-104Clinical Data
Topline data from planned Phase 2 trial of KIO-104 expected in 2026
posterior non-infectious uveitissource ↗
Drug Pipeline Intelligence
D32
Pipeline Score $10M
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored0.9x
rNPV / MCap Top 40%
Micro Cap (rank 548 of 911)
Percentile RankKiora Pharmaceuticals, Inc. faces pipeline headwinds (32/100), with $1.0B risk-adjusted pipeline value, led by 100 μg KIO-301 in Retinitis Pigmentosa (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100 μg KIO-301 Small molecule | Retinitis Pigmentosa | Phase 2 | NCT06628947 | 15% | $460M | RECRUITING | 36 | AVERAGE | C (50) | Aug 1, 2027 | MODERATE_RISK | LOW Jun 18, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
KIO-301 | retinitis pigmentosa | Phase 2 | 2024-03-25 | Positive results from the ABACUS-1 study indicate the potential efficacy and safety of KIO-301 in treating retinitis pigmentosa. Read More | Kiora Pharmaceuticals Reports 2023 Results Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California Read More | |
KIO-301 | retinitis pigmentosa | Phase 2 | 2024-03-25 | Positive results from the ABACUS-1 study indicate the potential efficacy and safety of KIO-301 in treating retinitis pigmentosa. Read More | Kiora Pharmaceuticals Reports 2023 Results Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California Read More | |
KIO-301 | retinitis pigmentosa | Phase 2 | 2024-03-25 | Positive results from the ABACUS-1 study indicate the potential efficacy and safety of KIO-301 in treating retinitis pigmentosa. Read More | Kiora Pharmaceuticals Reports 2023 Results Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KPRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KPRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KPRXKiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The event will feature an investor fireside chat, which will be accessible live and via replay for 90 days. Kiora is advancing therapies for retinal diseases, including KIO-301 for retinitis pigmentosa and KIO-104 for macular edema.
Read more →KPRXKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Kiora Pharmaceuticals presented preclinical data at the Epilepsy Foundation Pipeline Conference, showing that KIO-300 effectively suppressed seizure activity in a temporal lobe epilepsy model. The results indicate significant reductions in epileptiform activity, suggesting the drug's potential for broader neurological applications. Kiora aims to explore further therapeutic uses of KIO-300 beyond its current focus on vision restoration.
Read more →KPRXKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in
Kiora Pharmaceuticals has announced positive preclinical results at the Epilepsy Foundation Pipeline Conference regarding its ion channel modulator, KIO-300. The data showed that KIO-300 significantly suppressed seizure activity in a temporal lobe epilepsy model, with effects beginning 42 minutes post-treatment and persisting during follow-up periods. This suggests a promising therapeutic potential for KIO-300 beyond its initial applications in ophthalmology, indicating possible uses in treating epilepsy and other neurological disorders.
Read more →KPRXKiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update Encinitas, CA
Kiora Pharmaceuticals has reported positive first-quarter financial results for 2026 and updates on its clinical pipeline focusing on treatments for retinal diseases. The company sees strong patient enrollment in the Phase 2 ABACUS-2 study of KIO-301 and has validated its potential through a publication in Nature Medicine. Significant progress is also noted for the KLARITY study regarding KIO-104, with a pre-defined safety review upcoming. Moreover, Kiora has secured additional funding from a strategic equity financing, enhancing its operational runway into late 2028.
Read more →KPRXKiora Pharmaceuticals Announces Management Team Changes Encinitas, California
Kiora Pharmaceuticals announced management changes with the departure of Chief Development Officer Eric J. Daniels, M.D., MBA, effective April 17, 2026. The company expressed gratitude for his contributions while initiating a search for a successor. Kiora remains dedicated to its pipeline aimed at treating retinal diseases, with ongoing clinical trials KIO-301 and KIO-104 showing positive advancements in patient enrollment. The company continues to receive approvals for clinical trial progression, indicating a forward momentum in development.
Read more →KPRXKiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials Encinitas, California
Kiora Pharmaceuticals has reported its financial results for Q4 and full year 2025, detailing the advancement of its retinal disease treatments. The company has commenced two active Phase 2 clinical trials, with KIO-301 and KIO-104 both in patient dosing stages. Despite ending the year with a solid cash reserve that extends operations into late 2027, Kiora also faced a significant net loss partially due to an impairment charge. The firm is optimistic about its partnerships and pipeline progression, aiming for initial clinical data readouts in 2027.
Read more →KPRXIn addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and
Kiora Pharmaceuticals announced the closure of a private placement providing up to $24 million in gross proceeds, with $5 million received upfront and the remaining contingent on milestone-based warrants. The company intends to utilize these funds for general corporate purposes, including strategic business development and research efforts. The private placement involved the sale of common stock and warrants, with significant investors being Perceptive Advisors and ADAR1 Capital Management. This financial boost is expected to facilitate Kiora's ongoing development of therapies for retinal diseases.
Read more →KPRXKiora Pharmaceuticals Reports Third Quarter 2025 Results Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases Encinitas, California
Kiora Pharmaceuticals (NASDAQ: KPRX) has reported its third-quarter 2025 financial results, highlighting advancements in its clinical pipeline for retinal diseases. The company is currently conducting two actively enrolling Phase 2 clinical trials, KLARITY and ABACUS-2, aimed at treating retinal inflammation and retinitis pigmentosa. Kiora ended the quarter with $19.4 million in cash and reported a small net income, a significant improvement from the previous year's losses. The firm's ongoing financial management and collaborations are set to support its development efforts through to late 2027.
Read more →KPRXKiora Pharmaceuticals Reports Second Quarter 2025 Results Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases Encinitas, California
Kiora Pharmaceuticals has reported its financial results for Q2 2025, highlighting advancements in its therapeutic pipeline for retinal diseases. The company has initiated two Phase 2 clinical trials, KLARITY and ABACUS-2, targeting retinal inflammation and vision restoration, respectively. Kiora also strengthened the market exclusivity of KIO-104 and entered a partnership with Senju Pharmaceutical that could yield substantial financial benefits. Despite these advancements, Kiora continues to incur losses, reporting a net loss consistent with prior periods.
Read more →KPRX▲ +36.8%on this news
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia - Total potential deal value of $110 million plus royalties - Kiora to receive an immediate $1.25 million ex
Kiora Pharmaceuticals announced a partnership with Senju Pharmaceutical, granting Senju an exclusive option for the development and commercialization of KIO-301 for retinal diseases across key Asian markets. The agreement has a total potential value of $110 million, including an immediate $1.25 million option fee. KIO-301 is currently in Phase 2 trials and aims to offer therapeutic options for inherited retinal diseases, particularly retinitis pigmentosa. This deal is expected to enhance Kiora's financial stability and extend the commercial reach of KIO-301.
Read more →KPRXKiora Pharmaceuticals Reports First Quarter Results Initiating Two Phase 2 Trials for Treatment of Retinal Diseases Cash and Short-term Investments Expected to Fund Operations into Late 2027 Encinitas, California
Kiora Pharmaceuticals has reported its first quarter results for 2025, announcing the initiation of two Phase 2 clinical trials for KIO-104 and KIO-301, targeting retinal diseases. The company's cash and short-term investments are expected to fund operations until late 2027, providing a robust financial runway. While Kiora experienced a net loss this quarter, the approval for new trials and positive preclinical data strengthen its position in the field of retinal therapeutics. Ongoing patient enrollment and collaborations may further enhance the company's prospects.
Read more →KPRX▼ -5%on this news
Kiora Pharmaceuticals Reports 2024 Results Retinal Disease Drug Development Pipeline Continues to Advance Cash and Short-term Investments Expected to Fund Operations into 2027 Encinitas, California
Kiora Pharmaceuticals has announced positive developments in its retinal disease drug pipeline, including the initiation of two Phase 2 clinical trials for KIO-104 and KIO-301. The company ended 2024 with $26.8 million in cash, which is projected to fund operations until 2027. These trials aim to address important retinal disorders, with initial data expected in 2026. Despite a reported net loss in Q4 2024, the company is strategically positioned to advance its therapeutic candidates.
Read more →KPRXKiora Pharmaceuticals Reports Third Quarter Results Retinal Disease Pipeline Advancing Two Phase 2 Studies Encinitas, California
Kiora Pharmaceuticals reported its financial results for Q3 2024, highlighting advancements in its retinal disease pipeline, including two Phase 2 studies. The company has received approval to begin the ABACUS-2 trial for KIO-301 and is finalizing plans for the KLARITY trial for KIO-104, which targets multiple retinal inflammatory diseases. Kiora ended the quarter with $29 million in cash, indicating a strong financial position to support ongoing developments. The company anticipates increased research and development expenses as it begins patient enrollment for these studies.
Read more →KPRXDocument Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Encinitas, California
Kiora Pharmaceuticals has announced the receipt of Investigational New Drug approval to start the ABACUS-2 Phase 2 clinical trial for KIO-301, a treatment aimed at restoring vision in patients with retinitis pigmentosa. This trial will investigate the safety and efficacy of KIO-301 in a multi-center setup across Australia and enroll 36 patients. Notably, KIO-301 is a small molecule that activates in the presence of light, providing potential vision restoration regardless of individual gene mutations. The trial aims to validate breakthrough functional vision endpoints essential for subsequent registration studies in major regions including the US and Europe.
Read more →KPRXKiora Pharmaceuticals Reports Second Quarter Results Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Encinitas, California
Kiora Pharmaceuticals has reported its second-quarter results as it advances its pipeline targeting retinal diseases. The company is set to initiate two Phase 2 clinical trials for its innovative small molecules, KIO-301 and KIO-104. Kiora maintains a solid cash position, aiming for a runway through 2027, facilitating these developments. Notably, Kiora received Orphan Medicinal Product Designation from the EMA, which could bolster its position in the market. However, the company still faces financial challenges, including a net loss in the recent quarter.
Read more →KPRXDocument Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies Encinitas, CA
Kiora Pharmaceuticals has gained Orphan Medicinal Product Designation for KIO-301 from the European Medicines Agency, aimed at treating inherited retinal dystrophies. This designation grants Kiora significant market exclusivity and regulatory benefits in Europe, following similar status in the U.S. The company plans to advance clinical development with a Phase 2 trial set to begin soon. KIO-301 is designed as a new therapeutic approach to address vision loss due to genetic retinal disorders.
Read more →KPRXDocument Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors Ken Gayron to Step Down as a Member of the Company's Board
Kiora Pharmaceuticals has appointed Lisa Walters-Hoffert to its Board of Directors while Ken Gayron steps down due to other commitments. Walters-Hoffert, a seasoned biotech executive, will chair the audit committee and contribute her extensive experience in strategic development and finance to aid Kiora's growth. The company is actively working on advancing its investigational treatments, including KIO-301, and has secured funding to support its research efforts for at least two years. The change in leadership aims to strengthen Kiora's direction in developing novel therapies for retinal diseases.
Read more →KPRXKiora Pharmaceuticals Reports First Quarter Results Update on Pipeline of Drugs Targeting Retinal Disease Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Th a Open Innovation, exp
Kiora Pharmaceuticals has announced its first quarter financial results and updates on its retinal disease drug pipeline. Notably, the company plans to initiate a Phase 2 trial for KIO-301 for retinitis pigmentosa in Q4 2024 and a Phase 2 trial for KIO-104 in 2025. Kiora ended the quarter with $31.3 million in cash, benefiting from a strategic partnership with Th a Open Innovation. The collaboration is poised to significantly support the development of both KIO-301 and KIO-104, with potential implications for treating various retinal conditions.
Read more →KPRXKiora Pharmaceuticals Reports 2023 Results Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California
Kiora Pharmaceuticals reported its 2023 financial results and announced plans to initiate Phase 2 trials for its retinal disease treatments, KIO-301 and KIO-104, in 2024. The company secured a strategic partnership with TOI, gaining a $16 million upfront payment, which is expected to support operations through 2026. Positive results from the ABACUS-1 study indicate the potential efficacy and safety of KIO-301 in treating retinitis pigmentosa. Kiora also plans to pursue additional studies and orphan drug designations for its product candidates.
Read more →KPRX▲ +53.9%on this news
expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. Contact Information Investors kiorapharma.com
Kiora Pharmaceuticals has announced a successful private placement aimed at raising up to approximately $45 million. This includes an upfront financing of $15 million with the potential for an additional $30 million through warrant exercises. The funding will support the development of KIO-104 for posterior non-infectious uveitis and other inflammatory conditions. Notable healthcare investment firms are participating, indicating confidence in Kiora's pipeline and operations.
Read more →KPRX▼ -6.2%on this news· ran to +44% by day 1shared move
Kiora Pharmaceuticals and Th a Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases Total Deal Value of up to $301 Million includes $16 Million Up
Kiora Pharmaceuticals has entered a strategic partnership with Th a Open Innovation to develop and commercialize KIO-301 for inherited retinal diseases. The agreement involves a total deal value of $301 million, including an upfront payment of $16 million and potential future milestones. Kiora plans to initiate a Phase 2 clinical trial for retinitis pigmentosa in early 2024, following successful Phase I II data. The partnership aims to leverage TOI's resources for broader development and commercialization efforts while focusing initially on significant vision improvement in affected patients.
Read more →KPRXKiora Pharmaceuticals Reports Q3 2023 Results Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa Encinitas, California
Kiora Pharmaceuticals reported promising Q3 2023 results, highlighting the safe and effective profile of KIO-301 based on the ABACUS-1 study in retinitis pigmentosa. The company plans to further develop KIO-301 for other inherited retinal diseases through new Phase 2 trials. A meeting with the FDA is planned for Q4 2023 to discuss future clinical study designs and endpoints. Despite positive advancements, the company reported an increase in net loss year-over-year.
Read more →KPRXKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman Succeeds Paul Chaney Who is Retiring After Serving 17 Years
Kiora Pharmaceuticals has appointed Praveen Tyle, PhD, as its new Chairman, succeeding Paul Chaney who is retiring after 17 years. Tyle, who is already a director at the company, is expected to lead with valuable experience in guiding Kiora's development of new treatments for eye disease, particularly focusing on KIO-301's advancement. The CEO expressed gratitude to Chaney for his long-term contributions and highlighted the strategic direction under Tyle's leadership.
Read more →KPRXKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 Encinitas, CA
Kiora Pharmaceuticals announced that its Special Meeting of Stockholders, initially held on August 31, 2023, was adjourned to September 27 due to insufficient quorum. The company is seeking additional votes to meet the one-third voting power required for quorum. During this period, Kiora is working with a proxy solicitor to encourage stockholders to participate. If the necessary votes are not obtained, the meeting may need to be adjourned again, leading to additional expenses.
Read more →KPRXKiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress - Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concep
Kiora Pharmaceuticals reported positive preliminary data from its Phase 1 clinical trial of KIO-301 for treating Retinitis Pigmentosa during Q2 2023. The data demonstrated safety and tolerability at the lowest dose, prompting plans for higher dose trials. The company aims to focus on rare retinal diseases, expanding KIO-301's application to include Choroideremia and Stargardt's Disease. With a new strategy in place, Kiora is actively seeking partnerships while also pursuing clinical milestones and FDA discussions for its products.
Read more →KPRXBiotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
Kiora Pharmaceuticals, Inc. has appointed Carmine Stengone to its board of directors. Stengone, current President and CEO of Pipeline Therapeutics, brings valuable experience in developing precision medicines for neurodegenerative diseases. His background in small molecules and degenerative diseases is expected to guide Kiora's strategy and clinical development. The company continues to advance its promising pipeline, particularly focusing on KIO-301, which may restore vision for patients with retinitis pigmentosa.
Read more →KPRX▲ +5.5%on this news
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 Amendment eliminates $4.75M in near-term milestones Kiora would have owed to Sentrx Sentrx gains access to Kiora's
Kiora Pharmaceuticals and Sentrx Animal Care have amended their licensing agreement for the KIO-201 product candidate. The amendment allows Kiora to avoid up to $4.75M in near-term milestone payments while granting Sentrx access to Kiora's patents related to the use of hyaluronic acid technology with antibiotics in animal health. Kiora will continue to receive a royalty on net sales of products covered by these patents, enhancing its financial position and flexibility. The changes are expected to benefit both companies and support their respective innovations in veterinary care.
Read more →KPRX▼ -49.5%on this news
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering Encinitas, California--(Newsfile Corp.
Kiora Pharmaceuticals has announced the pricing of an underwritten public offering aimed at raising approximately $5.5 million. The offering includes common stock, convertible preferred stock, and multiple types of warrants. The expected closing date for this offering is June 6, 2023, pending customary closing conditions. This move is seen as a step to facilitate the company's ongoing development efforts for its ophthalmic disease treatments.
Read more →KPRXKiora Pharmaceuticals Reports First Quarter Results Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments Encinitas, CA
Kiora Pharmaceuticals reported significant advancements in their ocular drug pipeline during the first quarter of 2023. The company highlighted positive results from studies on KIO-301, which aims to improve light perception in patients with Retinitis Pigmentosa, and KIO-201, targeting chronic ocular wounds. Additionally, Kiora initiated a Phase 2 trial for KIO-101, focusing on ocular surface disease related to autoimmune conditions. The firm is positioned to continue enrollment in ongoing studies and plans to report more results within the year.
Read more →KPRX▲ +8.9%on this news
Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind Encinitas, California
Kiora Pharmaceuticals presented encouraging preliminary results from its clinical trial of KIO-301, an investigational treatment for retinitis pigmentosa. The treatment demonstrated the capability to restore light perception in patients with severe visual impairment. Initial data showed improvements in functional vision and neural activity in the visual cortex, suggesting significant potential for KIO-301 as a therapy for this condition. The trial aims to further evaluate the safety and efficacy of the drug, with plans for dose escalation and comprehensive reporting of results later this year.
Read more →KPRX▼ -9.4%on this news
Kiora Pharmaceuticals Reports 2022 Financial Results Provides Update on Clinical Development Progress
Kiora Pharmaceuticals has reported its 2022 financial results, highlighting progress in its clinical development of innovative treatments for rare eye diseases. The company is advancing three key product candidates, including the promising KIO-301 for Retinitis Pigmentosa, with early results indicating potential vision restoration. Kiora also plans to present additional data at the upcoming ARVO meeting. Despite achieving operational efficiencies, the company recorded a net loss of $13.6 million, which raises concerns about its financial health moving forward.
Read more →KPRX▲ +38.7%on this news· ran to +112% by day 1
Kiora Pharmaceuticals Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases Encinitas, California
Kiora Pharmaceuticals has received approval for a Phase 2 study of KIO-101, intended for the treatment of ocular manifestations in autoimmune diseases, particularly rheumatoid arthritis. This multi-center trial will involve 120 patients and aims to assess the safety and efficacy of KIO-101 eye drops, which address significant ocular symptoms that current treatments do not effectively manage. The company believes this drug could serve as a viable option for patients suffering from ocular surface disease, potentially impacting approximately 3.43 million people in the U.S.
Read more →KPRXKiora Pharmaceuticals, Inc. NASDAQ: KPRX January 2023 | Corporate Outlook 2 Forward Looking Statements Some of the statements in this presentation are "forward - looking" and are made pursuant to the safe harbor provisio
Kiora Pharmaceuticals, Inc. has provided an overview of its corporate outlook and ongoing clinical development efforts. The company is advancing several product candidates, including KIO-101, KIO-201, and KIO-301, which target rare ophthalmic diseases. KIO-301 has received orphan drug designation, while a Phase 2 trial of KIO-101 is set to initiate in 2023. Despite positive developments, the company acknowledges various risks and uncertainties that could impact the commercial success of their products.
Read more →KPRX▼ -35.8%on this news
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants Salt Lake City, Utah--(Newsfile Corp.
Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants Salt Lake City, Utah--(Newsfile Corp. - November 18, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today it ha
Read more →KPRXKiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Salt Lake City, Utah--(
Kiora Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Salt Lake City, Utah--(October 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that it has received a Bid Price Compliance Letter from The Nasdaq Stock
Read more →KPRX▼ -10.1%on this news
Kiora Pharmaceuticals to Implement 1-for-40 Reverse Split Salt Lake City, Utah -- (
Pharmaceuticals to Implement 1-for-40 Reverse Split Salt Lake City, Utah -- (September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock. Following th
Read more →KPRX▲ +21%on this news
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance Salt Lake City, Utah--(Newsfile Corp.
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of F
Read more →KPRX▼ -39.8%on this news
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering Salt Lake City, Utah--(Newsfile Corp.
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering Lake City, Utah--(Newsfile Corp. - July 22, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gr
Read more →KPRX▲ +10%on this news
Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Salt Lake City, Utah
Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) Salt Lake City, Utah -- May 31, 2022 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the
Read more →KPRXKiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board SALT LAKE CITY, UT, Feb 1, 2022 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independe
Read more →KPRXCORPORATE OVERVIEW January 2022 2 Forward Looking Statements Some of the statements in this press release are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Re
CORPORATE OVERVIEW January 2022 2 Forward Looking Statements Some of the statements in this press release are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These "forward - looking" statements inc
Read more →KPRXKiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors SALT LAKE CITY, UT, Dec 15, 2021 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. H
Read more →KPRXKiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease SALT LAKE CITY, UT, Dec 14, 2021 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced topline data from its ve
Read more →KPRXKiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities. “We recen
Read more →KPRXEyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy
EyeGate is Now Kiora Pharmaceuticals; Provides Sharpened Clinical Development Strategy SALT LAKE CITY, UT, November 8, 2021 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will tra
Read more →KPRXEyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. EyeGate adds Bayon Therapeutics' portfolio of vision-restoring small molecules to
EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. Bayon Therapeutics' portfolio of vision-restoring small molecules to its development pipeline WALTHAM, MA, October 26, 2021 - EyeGate Pha
Read more →KPRXEyeGate Pharmaceuticals (NASDAQ: EYEG) Sept 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform
EyeGate Pharmaceuticals (NASDAQ: EYEG) Sept 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These "forward - looking" statements include
Read more →KPRXEyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules WALTHAM, MA
Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq MA, August 10, 2021 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and
Read more →KPRXEyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceuti
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small mo
Read more →KPRXTreating inflammatory and immune diseases May 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Refor
Treating inflammatory and immune diseases May 2021 2 Forward Looking Statements Some of the statements are "forward - looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These "forward - looking" statements includ
Read more →KPRXEyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors WALTHAM, MA
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors WALTHAM, MA, April 01, 2021 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing products for treating inflammato
Read more →KPRXLead Independent Director Charter If the Chairman of the Board of EyeGate Pharmaceutical, Inc. (the "Company") is also an employee of the Company or its subsidiaries, then the independent members of the Board of Director
Lead Independent Director Charter If the Chairman of the Board of EyeGate Pharmaceutical, Inc. (the "Company") is also an employee of the Company or its subsidiaries, then the independent members of the Board of Directors will annually elect with a majority vote an independent
Read more →KPRXEyeGate Enters Into Agreement for $8.0 Million Private Placement WALTHAM, MA
EyeGate Enters Into Agreement for $8.0 Million Private Placement WALTHAM, MA, January 06, 2021 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune d
Read more →KPRXEyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma Expands Pipeline Beyond Ophthalmology with PP-001 , a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Me
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Ta
Read more →KPRXNASDAQ: EYEG Corporate Presentation September 2020 TB D 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements rel
NASDAQ: EYEG Corporate Presentation September 2020 TB D 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's OBG and EGP - 437
Read more →KPRXNASDAQ: EYEG Corporate Presentation 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospec
NASDAQ: EYEG Corporate Presentation 2 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's OBG and EGP - 437 product candidates ,
Read more →KPRXEyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study WALTHAM, MA
Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study MA, March 31, 2020 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announ
Read more →KPRXEyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules WALTHAM, MA
Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MA, December 31, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorde
Read more →KPRXEyeGate Pharma Receives $1.9 Million From Exercised Warrants WALTHAM, MA
Pharma Receives $1.9 Million From Exercised Warrants WALTHAM, MA, December 17, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the exercise of warrants subsequent
Read more →KPRXEyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study WALTHAM, MA
Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study WALTHAM, MA, December 2, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the
Read more →KPRXEyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study WALTHAM, MA
Pharma Hits Primary Endpoint in PRK Pivotal Study WALTHAM, MA, November 22, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today
Read more →KPRXEyeGate Enters Into Agreement for $1.9 Million Private Placement WALTHAM, MA
EyeGate Enters Into Agreement for $1.9 Million Private Placement WALTHAM, MA, September 30, 2019 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today anno
Read more →KPRXEyeGate Pharma Regains Nasdaq Listing Compliance
Pharma Regains Nasdaq Listing Compliance WALTHAM, Mass., Sept. 23, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that the
Read more →KPRXNASDAQ: EYEG Corporate Presentation Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects
NASDAQ: EYEG Corporate Presentation Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's OBG and EGP - 437 product candidates , f
Read more →KPRXEYEGATE PHARMA ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE AUGUST 30, 2019 WALTHAM, MA
PHARMA ANNOUNCES REVERSE STOCK SPLIT EFFECTIVE AUGUST 30, 2019 WALTHAM, MA, August 29, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, anno
Read more →KPRXEyeGate Pharma Receives Positive Nasdaq Listing Determination
Pharma Receives Positive Nasdaq Listing Determination WALTHAM, Mass., May 14, 2019 (ACCESSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for the co
Read more →KPRXNASDAQ: EYEG Corporate Presentation Two Versatile Platforms Moving Towards Commercialization December 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant
NASDAQ: EYEG Corporate Presentation Two Versatile Platforms Moving Towards Commercialization December 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to t
Read more →KPRXEYEGATE PHARMA ANNOUNCES POSITIVE RESULTS IN SECOND PRK STUDY Data confirms results from earlier study
ANNOUNCES POSITIVE RESULTS IN SECOND PRK STUDY results from earlier study WALTHAM, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today announced top-line data from its study evaluating the potential of EyeGate's Ocular Bandage Gel (OBG)
Read more →KPRXEyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care
EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care WALTHAM, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform techn
Read more →KPRXEyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules
EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules WALTHAM, Mass., Sept. 25, 2018 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating dis
Read more →KPRXNASDAQ: EYEG Investor Presentation Two Versatile Platforms Moving Towards Commercialization September 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant
NASDAQ: EYEG Investor Presentation Two Versatile Platforms Moving Towards Commercialization September 2018 Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncertainties, including statements relating to t
Read more →KPRXEyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis WALTHAM, MA., September 04 , 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with
Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis WALTHAM, MA., September 04, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and d
Read more →KPRXEyeGate Pharmaceuticals Announces New Board Member, Steven Boyd
EyeGate Pharmaceuticals Announces New Board Member, Steven Boyd WALTHAM, Mass., May 16, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating
Read more →KPRXEyeGate Announces Completion of $11.25 Million Public Offering
EyeGate Announces Completion of $11.25 Million Public Offering WALTHAM, Mass., April 17, 2018 - EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating d
Read more →KPRXEyeGate Announces $11.25 Million Public Offering
Announces $11.25 Million Public Offering Mass., April 13, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the
Read more →KPRXNASDAQ: EYEG EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Two Versatile Platforms Moving Towards Commercialization Follow us on Facebook, LinkedIn and Twitter Fo
Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company's lead product EGP - 437, for the timing and outcom
Read more →KPRXwww.eyegatepharma.com NASDAQ: EYEG NASDAQ: EYEG EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com OBG: The Ocular Liquid Bandage A crosslinked hyaluronic acid (CMHA -
www.eyegatepharma.com NASDAQ: EYEG Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company's lead product E
Read more →KPRXEyeGate Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery EGP-437 demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints
Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery demonstrated better clinical performance than vehicle control but did not meet its co-primary endpoints Mass., February 05, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) a clinical-stage, specia
Read more →KPRXCORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Two Versatile Platforms Moving Towards Commercialization Forward Looking Statements Some of t
CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Two Versatile Platforms Moving Towards Commercialization Forward Looking Statements Some of the matters discussed in this presentation contain forward -
Read more →KPRXEyeGate Promotes Sarah Romano to Chief Financial Officer Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase
EyeGate Promotes Sarah Romano to Chief Sarah Romano, elevated from Interim CFO, will lead finance effort during transition to commercialization phase WALTHAM, Mass., January 04, 2018 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage
Read more →KPRXTwo Versatile Platforms Moving Towards Commercialization Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements rel
Two Versatile Platforms Moving Towards Commercialization Some of the matters discussed in this presentation contain forward - looking statements that involve significant risks and uncerta inties, including statements relating to the prospects for the Company's EGP - 437 and OBG
Read more →KPRXProviding innovative products that enhance drug efficacy and patient compliance to improve vision CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma
Providing innovative products that enhance drug efficacy and patient compliance to improve vision CORPORATE PRESENTATION EyeGate Pharmaceuticals, Inc. 271 Waverley Oaks Road, Suite 108 Waltham, MA 02452 www.eyegatepharma.com Forward Looking Statements Some of the matters discuss
Read more →KPRXEyeGate Launches Social Media Pages to Enhance Investor and Trade Relationships WALTHAM, Mass., Sept ember 11, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage specialty
Launches Social Media Pages to Enhance Investor and Trade Relationships Mass., September 11, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company focused on developing and commercializing products u
Read more →KPRXEyeGate Announces Completion of $10.0 Million Public Offering
Announces Completion of $10.0 Million Public Offering Mass., June 14, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders
Read more →KPRXEyeGate Announces $10.0 Million Public Offering
Announces $10.0 Million Public Offering WALTHAM, Mass., June 9, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of
Read more →KPRXEyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel
Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel Mass., May 4, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company that focuses on developing and co
Read more →KPRXEyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this pr
EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involv
Read more →KPRXInternational Headquarters 2150 St. Elz ar Blvd. West Laval, Quebec H7L 4A8 Phone: 514.744.6792 Fax: 514.744.6272 Contact Information: Valeant EyeGate Pharmaceuticals Elif McDonald Lee Roth / Janhavi Mohite 514-856-3855
St. Elz ar Blvd. West Contact Information: Valeant EyeGate Pharmaceuticals Elif McDonald Lee Roth / Janhavi Mohite 514-856-3855 646-536-7012 / 7026 877-281-6642 (toll free) lroth@theruthgroup.com / jmohite@theruthgroup.com elif.mcdonald@valeant.com Chris Kittredge/Jared Levy
Read more →KPRXEyeGate Pharmaceuticals Announces Executive Promotions Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations,
EyeGate Pharmaceuticals Announces Executive Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations, respectively WALTHAM, Mass., February 06, 2017 - EyeGate Pharmaceu
Read more →KPRXEyeGate Pharmaceuticals, Inc.
EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 40 82 140 147 189 107 177 194 217 109 141 72 254 215 84 176 216 190 142 163 194 241 249 244 191 201 221 25 52 87 1 Forward Looki
Read more →KPRXFDA Confirms a 510(k) De Novo Path for EyeGate's Device, the Ocular Bandage Gel, Following Pre-Submission Meeting Top-Line Data from First-in-Human Pilot Study Expected by Year-End 2016
Confirms a 510(k) De Novo Path for EyeGate's Device, the Ocular Bandage Gel, Following Pre-Submission Meeting Data from First-in-Human Pilot Study Expected by Year-End 2016 Mass., November 17, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a
Read more →KPRXEyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this pr
Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements that involv
Read more →KPRXEyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients Mass., August 1, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmac
Read more →KPRXEyeGate Announces Completion of $3.77 Million Registered Direct Offering
Announces Completion of $3.77 Million Registered Direct Offering Mass., June 30, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery sy
Read more →KPRXEyeGate Announces $3.77 Million Registered Direct Offering
Announces $3.77 Million Registered Direct Offering Mass., June 27, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for trea
Read more →KPRXEyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation Forward Looking Statements Some of the matters discussed in this pres
Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation Forward Looking Statements Some of the matters discussed in this presentation contain forward-looking statements that involve
Read more →KPRXEyeGate Pharma Announces At The Market Issuance Program Waltham, Mass.
EyeGate Pharma Announces At The Market Waltham, Mass., May 24, 2016 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (the "Company") announced today that it has entered into an At The Market Issuance ("ATM") Sales Agreement, dated May 24, 2016, with H.C. Wainwright & Co., LLC (t
Read more →KPRXEyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Acquisition of Jade Therapeutics 1 Forward Looking Statements Some of the matters discussed
EyeGate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Acquisition of Jade Therapeutics 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statements t
Read more →KPRXEyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation January 2016 1 Forward Looking Statements Some of the matters discuss
Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Corporate Presentation January 2016 1 Forward Looking Statements Some of the matters discussed in this presentation contain forward - looking statement
Read more →KPRXEyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Rodman & Renshaw Annual Global Investment Conference 09 September 2015 1 Forward Looking Sta
Eyegate Pharmaceuticals, Inc. Providing innovative products that enhance drug efficacy and patient compliance to improve vision Rodman & Renshaw Annual Global Investment Conference 09 September 2015 1 Forward Looking Statements Some of the matters discussed in this presentation
Read more →KPRXC O M P A N Y I N T E R V I E W EyeGate Pharmaceuticals, Inc. (EYEG) STEPHEN FROM has served as the President, Chief Executive Officer and Director of EyeGate Pharmaceuticals, Inc., since October 2005. Prior to joining E
EyeGate Pharmaceuticals, SECTOR - PHARMACEUTICALS (AZC611) TWST: Could you provide a brief overview of the company and also talk about why it was now that you've decided to go public? From: EyeGate Pharmaceuticals focuses on the ophthalmic area, and what we actually have is a
Read more →KPRXEyeGate Pharmaceuticals Announces Pricing of $10,000,000 Public Offering of Common Stock and Warrants
EyeGate Pharmaceuticals Announces Pricing of $10,000,000 of Common Stock and Warrants WALTHAM, Mass., July 30, 2015 - Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercia
Read more →KPRXEyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis Company to Receive Upfront Cash Payment, Milestones and Royalties on Sales of Product Waltham, MA
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis Company to Receive Upfront Cash Payment, Milestones and Royalties on Sales of Product Waltham, MA, July 10, 2015 -Eyegate Pharmaceuticals, Inc. (OTCQB: EYEG) ("EyeGate"
Read more →Competitive Position
How KPRX ranks across every disease it competes inCompetitive Position is a premium feature
See how KPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial